CD4 and myeloid sarcoma: Of clinical relevance, however, may be recent findings reporting (i) a negative predictive value of 88%, if a CD4/CD8 T cell ratio <5.0 is combined with an absence of pleocytosis [58], (ii) that IL-6 elevations of >50 pg/mL combined with an increased CD4/CD8 T cell ratio indicate relapse in active neurosarcoidosis [59], and (iii) that activated CD4 T cells in CSF combined with plasma cells in blood differentiate neurosarcoidosis from MS [60].